Antitumor Activity of Cannabinoids and Their Interaction with Chemotherapy: A Systematic Review and Meta-Analysis of Preclinical Evidence
Pharmaceuticals · 14.05.2026 · 19 (5) · 768
DOI: 10.3390/ph19050768 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmaceuticals, online erschienen am 14.05.2026. Verfasst von Ioana Creangă-Murariu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Semmelweis University, Semmelweis University, Research and Innovation Fund, Health Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cannabinoids are studied as anticancer agents, but their effects vary across tumors, compounds, and experimental settings, underscoring the need to define consistent patterns. Our objective was to map cannabinoid efficacy across cancer preclinical models and identify tumor settings with the greatest translational promise.
Methods
The protocol was registered on PROSPERO (CRD42025543744); PubMed, Embase, and CENTRAL were searched on 4 April 2024 for in vitro and in vivo studies assessing cannabinoid antitumor effects alone or with chemotherapy versus vehicle or chemotherapy only. Random-effects models yielded pooled mean differences (MD) with 95% confidence intervals (CI). MDs of viable cells were calculated for in vitro assays and tumor volume (mm3) for in vivo studies. Reports of various compounds, cannabidiol (CBD), tetrahydrocannabinol (THC) or synthetic cannabinoids, were pooled.
Results
We included 189 studies in the final analysis. In vitro, cannabinoids reduced cell viability modestly overall, with significant effects in glioblastoma (MD −18.77 [CI: −27.15; −10.39]) and a nonsignificant trend in breast cancer (MD −6.75 [CI: −13.90; 0.40]). For in vivo, monotherapy showed the most consistent efficacy in glioblastoma, significantly reducing tumor volume by MD −980.58 mm3; [CI: −1270.2; −690.88]. Addition to temozolomide produced a favorable but nonsignificant decrease of MD −220.65 mm3; [CI: −579.34; 138.03, vs. temozolomide]. In breast cancer, cannabinoids achieved smaller yet significant tumor reductions (MD −402.64 mm3); [CI: −671.84; −133.45]. Synthetic agents had the largest effect (MD −1295.19 mm3); [CI: −1664.33; −928.05] -CBD plus doxorubicin vs. doxorubicin). Lung cancer (MD −562.17 mm3); [CI: −693.99; −430.35] and prostate cancer (MD −1136.59 mm3); [95% CI: −1320.97; −952.21] also had a significant response, whereas colon, pancreatic, and hepatocellular carcinoma models showed inconsistent or null responses.
Conclusions
Cannabinoids show promise as adjuncts in oncotherapy, particularly in glioblastoma and breast cancer, to enhance chemotherapy efficacy. These findings should be interpreted with caution given the high inter-study heterogeneity typical of preclinical research and should be considered hypothesis-generating, warranting further validation in standardized and clinically relevant models.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.
- Advanced Center for Research and Development in Experimental Medicine "Prof. Ostin C. Mungiu", Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Medical Oncology-Radiotherapy Department, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Department of Radiology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
- Pharmacy Faculty, Semmelweis University, 1085 Budapest, Hungary.
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1085 Budapest, Hungary.
ORCID-Profile: Ioana Creangă-Murariu, Ioana-Irina Rezuș, Brigitta Teutsch, Bogdan-Ionel Tamba, Stefania Bunduc
Förderung
- Semmelweis University
- Semmelweis University, Research and Innovation Fund
- Health Program
Zitieren
APA
Creangă-Murariu, I., Rezuș, I. I., Karami, R., Makolli, A., Chifu, C., Rancz, A., Sipos, Z., Ferdinandy, P., Papp, R., Teutsch, B., Tamba, B. I., Hegyi, P., & Bunduc, S. (2026). Antitumor Activity of Cannabinoids and Their Interaction with Chemotherapy: A Systematic Review and Meta-Analysis of Preclinical Evidence. Pharmaceuticals, 19(5), 768. https://doi.org/10.3390/ph19050768
Vancouver
Creangă-Murariu I, Rezuș II, Karami R, Makolli A, Chifu C, Rancz A, et al. Antitumor Activity of Cannabinoids and Their Interaction with Chemotherapy: A Systematic Review and Meta-Analysis of Preclinical Evidence. Pharmaceuticals. 2026;19(5):768. doi:10.3390/ph19050768
BibTeX
@article{CreangMurariu2026,
author = {Creangă-Murariu, Ioana and Rezuș, Ioana-Irina and Karami, Roshanak and Makolli, Amir and Chifu, Codrin and Rancz, Anett and Sipos, Zoltán and Ferdinandy, Péter and Papp, Renáta and Teutsch, Brigitta and Tamba, Bogdan-Ionel and Hegyi, Péter and Bunduc, Stefania},
title = {Antitumor Activity of Cannabinoids and Their Interaction with Chemotherapy: A Systematic Review and Meta-Analysis of Preclinical Evidence},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {5},
pages = {768},
doi = {10.3390/ph19050768}
}
EUVIMED